ArticleCell2019
Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish.
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 171 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
171citing papers in PubMed, 2 pooled it
18.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
171 citing papers in PubMed, 2 syntheses or guidelines pooled it, 259 citations in OpenAlex.
- Advancements in Zebrafish Models for Breast Cancer Research: Unveiling Biomarkers, Targeted Therapies, and Personalized Medicine.Medical science monitor : international medical journal of experimental and clinical research · 2023Pooled it
- Pooled it
- Preclinical and Virtual Models of Mucosal Melanoma: Bridging Translational Gaps in a Rare and Lethal Cancer.Pigment cell & melanoma research · 2026Review
- Glutamate decarboxylase 1 (GAD1) suppresses the progression of glioblastoma through GSK3β/β-catenin pathway.Cell death discovery · 2026Article
- Review
- Fluid shear stress activates a targetable mechano-metastatic cascade to promote medulloblastoma metastasis.Nature biomedical engineering · 2026Article
- In Vivo Prostate Cancer Modelling: From the Pre-Clinical to the Clinical Setting.Life (Basel, Switzerland) · 2026Review
- Zebrafish as a multimodal platforms for anti-inflammatory phytomedicine discovery and translation.Frontiers in pharmacology · 2026Review
- The PIK3CA/AKT pathway drives therapy resistance in rhabdomyosarcoma.Nature communications · 2025Article
- Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs.Chemical reviews · 2025Review
- Understanding the toxicity induced by radiation-triggered neuroinflammation and the on-demand design of targeted peptide nanodrugs.Signal transduction and targeted therapy · 2025Article
- Zebrafish Models of Induced Lymphangiogenesis: Current Advancements and Therapeutic Discovery.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Zebrafish as a Model for Translational Immuno-Oncology.Journal of personalized medicine · 2025Review
- Insights into human melanocyte development and characteristics through pluripotent stem cells combined with single-cell sequencing.iScience · 2025Article
- PDX models for functional precision oncology and discovery science.Nature reviews. Cancer · 2025Review
- Article
- Small Fish, Big Answers: Zebrafish and the Molecular Drivers of Metastasis.International journal of molecular sciences · 2025Review
- S100P is a ferroptosis suppressor to facilitate hepatocellular carcinoma development by rewiring lipid metabolism.Nature communications · 2025Article
- Automation in microinjection for zebrafish pericardial space with image-based motion control and batch agarose microplate.PloS one · 2025Article
- Effects of realgar-indigo naturalis formula on a zebrafish tumor xenograft model induced by human acute promyelocytic leukemia cells: antitumor activity, hepatotoxicity, and transcriptomic analysis.Frontiers in pharmacology · 2025Article
111 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
28 authors at 5 institutions in 1 country.
Chuan YanMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, USA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02139, USA.
Dalton C BrunsonMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, USA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Bethesda, MD 20815, USA.
Qin TangMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, USA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Bethesda, MD 20815, USA.
Daniel DoMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, USA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Bethesda, MD 20815, USA.
Nicolae A IftimiaMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, USA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02139, USA.
John C MooreMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, USA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02139, USA.
Madeline N HayesMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, USA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02139, USA.
Alessandra M WelkerMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, USA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02139, USA.
Elaine G GarciaMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, USA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02139, USA.
Taronish D DubashMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Xin HongMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Benjamin J DrapkinMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
David T MyersMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Sarah PhatMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Angela VolorioMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, USA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Dieuwke L MarvinMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Matteo LigorioMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Lyle DershowitzMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, USA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02139, USA.
Karin M McCarthyMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, USA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02139, USA.
Murat N KarabacakShriners Hospitals for Children-Boston, MA 02114, USA; Center for Engineering in Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02114, USA.
Jonathan A FletcherDepartment of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Dennis C SgroiMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, USA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
John A IafrateMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, USA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Shyamala MaheswaranMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Nick J DysonMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Daniel A HaberMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Howard Hughes Medical Institute, Bethesda, MD 20815, USA.
John F RawlsDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA.
David M LangenauMolecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, MA 02129, USA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02139, USA. Electronic address: dlangenau@mgh.harvard.edu.
Harvard University · USHoward Hughes Medical Institute · USBrigham and Women's Hospital · USDuke University · USShriners Hospitals for Children - Erie · US
Funding
Modeling Metastasis and Acquired Drug Resistance Using Circulating Tumor CellsR01CA129933 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel A. Haber · 2008 to 2026
$7.5MImmune Compromises Zebrafish for Cell TransplantationR24OD016761 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI LANGENAU, DAVID MICHAEL · 2013 to 2021
$5.2MGenetics of RhabdomyosarcomaR01CA154923 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LANGENAU, DAVID MICHAEL · 2011 to 2021
$3.8MUsing patient-derived models to understand drug responses in SCLCU01CA220323 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DYSON, NICHOLAS J · 2018 to 2022
$3.1MOncogenic pathways and therapeutic targets in T cell acute lymphoblastic leukemiaR01CA211734 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LANGENAU, DAVID MICHAEL · 2017 to 2021
$1.9MStem cell self-renewal programs in rhabdomyosarcomaR01CA215118 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LANGENAU, DAVID MICHAEL · 2018 to 2022
$1.9MNew models and therapeutic approaches in alveolar rhabdomyosarcomaR01CA226926 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LANGENAU, DAVID MICHAEL · 2018 to 2022
$1.9MHoward Hughes Medical InstituteNCI NIH HHS R01 CA129933NCI NIH HHS R01 CA154923NCI NIH HHS R01 CA211734NCI NIH HHS R01 CA215118NCI NIH HHS R01 CA226926NCI NIH HHS U01 CA220323NIH HHS R24 OD016761
Abstract
Xenograft cell transplantation into immunodeficient mice has become the gold standard for assessing pre-clinical efficacy of cancer drugs, yet direct visualization of single-cell phenotypes is difficult. Here, we report an optically-clear prkdc
Indexed as
Muscle NeoplasmsRhabdomyosarcomaAnimalsAnimals, Genetically ModifiedAntineoplastic Combined Chemotherapy ProtocolsFemaleHeterograftsHumansK562 CellsMaleNeoplasm TransplantationPhthalazinesPiperazinesTemozolomideXenograft Model Antitumor AssaysZebrafisholaparibPhthalazinesPiperazinesTemozolomidebreast canceril2rgimmune deficientmelanomaprkdcrhabdomyosarcomaSCIDxenograftzebrafish
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.